Seyyed Amir Siadati1*, Mohammad Ali Ebrahimzadeh2, and Akbar Dadras3
1 Pharmaceutical Sciences Research Center, Hemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, Iran
2 Department of Medicinal Chemistry, The head Sari school of pharmacy, Sari, 4815733971, Iran
3 R&D Department, Shimi-Daruee Pharmaceutical Company, TPICO, Tehran, Iran
* Correspondence to: Chemistry_2021@yahoo.com
Abstract
Artificial intelligence (AI) is rapidly transforming the pharmaceutical industry, offering unprecedented opportunities to accelerate drug discovery, optimize synthesis, and improve quality control. Despite its potential, unmonitored AI implementation carries significant risks, including errors in prediction, regulatory non-compliance, and ethical challenges. This perspective article explores the integration of AI across key stages of pharmaceutical research and development, including drug design, clinical trials, synthesis, analysis, and formulation, with an emphasis on human-in-the-loop supervision. We highlight areas where AI can deliver maximum efficiency gains and identify stages that require intensive human oversight to ensure safety, reliability, and regulatory adherence. By examining current applications and limitations, this article proposes a framework for combining AI capabilities with expert human judgment, aiming to enhance productivity while minimizing risk. Finally, we discuss future directions, including adaptive AI systems and hybrid models that promise to transform pharmaceutical operations without compromising ethical and scientific standards.
